IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors Seeking Alpha / - 2 hours ago
Science and Technology Daily: Tech with Heart AI for Good AI with a Human Touch Seeking Alpha / - 2 hours ago
Comments